Real-time Estimate Cboe BZX 09:34:47 2024-05-21 am EDT 5-day change 1st Jan Change
45.17 USD -0.66% Intraday chart for Qiagen N.V. +2.57% +1.56%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
QIAGEN NV : Berenberg maintains a Buy rating ZD
Qiagen's Updated Clinical Decision Support Platform Secures EU Certification MT
QIAGEN Receives European IVDR Certification for QIAGEN Clinical Insight Interpret CI
Qiagen Receives FDA Clearance for Clinical Use of Respiratory Infection Test MT
Qiagen Obtains US FDA Clearance for Respiratory Syndromic Testing Panel MT
Qiagen, US FBI to Jointly Develop Digital PCR Assay for Forensics MT
QIAGEN Partners with FBI to Develop Digital PCR Assay for QIAcuity for Use in Forensics CI
QIAGEN  Announces the Availability of QCI Secondary Analysis CI
QIAGEN NV : Berenberg reaffirms its Buy rating ZD
QIAGEN : A decent start to 2024; guidance unchanged Alphavalue
QIAGEN NV : Deutsche Bank reiterates its Buy rating ZD
Qiagen Seeks Acquisitions CI
Transcript : Qiagen N.V., Q1 2024 Earnings Call, Apr 30, 2024
QIAGEN NV : Jefferies remains Neutral ZD
QIAGEN NV : UBS remains Neutral ZD
QIAGEN NV : UBS remains Neutral ZD
QIAGEN NV : UBS sticks Neutral ZD
Qiagen Q1 Adjusted Earnings, Sales Decline; Q2 Outlook Issued, 2024 Guidance Affirms -- Shares Fall After Hours MT
Qiagen N.V. Reaffirms Earnings Guidance for the Year 2024 CI
Qiagen N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
QIAGEN N.V. Announces Launch of QIAseq xHYB Mycobacterium Biotechnology Panel for Research Use CI
European Equities Close Higher in Monday Trading; EC Probes TikTok Over Possible DSA Violations MT
QIAGEN NV : Deutsche Bank reiterates its Buy rating ZD
Qiagen N.V. Strengthens Its Portfolio for Cancer Research, Showcases Latest Product Launches At AACR Annual Meeting 2024 CI
Mybio Are the New Exclusive Partner for Qiagen in Ireland & Northern Ireland CI
Chart Qiagen N.V.
More charts
Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Mean consensus
Number of Analysts
Last Close Price
45.47 USD
Average target price
50.21 USD
Spread / Average Target
  1. Stock Market
  2. Equities
  3. QGEN Stock
  4. News Qiagen N.V.
  5. Morgan Stanley Upgrades Qiagen to Overweight From Equalweight, Adjusts Price Target to $49.48 From $51
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.